Danma Bio is an innovative drug developer. Danma Bio has established its own GAMID® (Genetics-centric And Multi-omics Integrated Data) target discovery platform, based on massive human disease genome-wide association study (GWAS) data , and integrate the growing multi-omics data such as proteome GWAS and transcriptome GWAS, large-scale and systematic application of Mendelian randomization (Mendelian Randomization) virtual clinical trials to discover and verify new drug targets, combined with independent antibody research and development system , Established a macromolecule drug development platform focusing on tumor immunity, tumor microenvironment, and autoimmune diseases. Recently, Danma Biotech completed a round of financing of nearly 20 million US dollars, led by Longpan Investment, followed by Delian Capital. This round of financing will be mainly used for the advancement of pipelines and the construction of technology platforms. Sole financial advisor to the transaction.
This article is transferred from: https://www.itjuzi.com/investevent/13739323
This site is only for collection, and the copyright belongs to the original author.